Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas V Faller

Showing results (121-130 of 126) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 126 results.
Blood Advances|August 2, 2023
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 studyBradley Haverkos, Onder Alpdogan, Robert Baiocchi, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Blood Advances|June 21, 2022
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AMLLionel Adès, Larisa Girshova, Vadim A Doronin, et al.
Blood|January 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLRonan T Swords, Steven Coutre, Michael B Maris, et al.
Gynecologic Oncology|November 7, 2025
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191]Premal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
Gynecologic Oncology|June 3, 2025
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancerPremal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
Pageof 13

Showing results (121-130 of 126) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 126 results.
Blood Advances|August 2, 2023
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 studyBradley Haverkos, Onder Alpdogan, Robert Baiocchi, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Blood Advances|June 21, 2022
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AMLLionel Adès, Larisa Girshova, Vadim A Doronin, et al.
Blood|January 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLRonan T Swords, Steven Coutre, Michael B Maris, et al.
Gynecologic Oncology|November 7, 2025
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191]Premal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
Gynecologic Oncology|June 3, 2025
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancerPremal H Thaker, Debra L Richardson, Andrea R Hagemann, et al.
Pageof 13